TY - JOUR AU - Pauken, K. r. i. s. t. e. n. E. AU - Dougan, M. i. c. h. a. e. l. AU - Rose, N. o. e. l. R. AU - Lichtman, A. n. d. r. e. w. H. AU - Sharpe, A. r. l. e. n. e. H. PY - 2019 DA - 2019// TI - Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities JO - Trends in Immunology VL - 40 UR - https://doi.org/10.1016/j.it.2019.04.002 DO - 10.1016/j.it.2019.04.002 ID - Pauken2019 ER - TY - JOUR AU - Postow, M. A. AU - Sidlow, R. AU - Hellmann, M. D. PY - 2018 DA - 2018// TI - Immune-related adverse events associated with immune checkpoint blockade JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMra1703481 DO - 10.1056/NEJMra1703481 ID - Postow2018 ER - TY - JOUR AU - Dougan, M. AU - Dranoff, G. AU - Dougan, S. K. PY - 2019 DA - 2019// TI - Cancer immunotherapy: beyond checkpoint blockade JO - Annual Review of Cancer Biology VL - 3 UR - https://doi.org/10.1146/annurev-cancerbio-030518-055552 DO - 10.1146/annurev-cancerbio-030518-055552 ID - Dougan2019 ER - TY - JOUR AU - Pardoll, D. M. PY - 2012 DA - 2012// TI - The blockade of immune checkpoints in cancer immunotherapy JO - Nat Rev Cancer VL - 12 UR - https://doi.org/10.1038/nrc3239 DO - 10.1038/nrc3239 ID - Pardoll2012 ER - TY - JOUR AU - Postow, M. A. AU - Callahan, M. K. AU - Wolchok, J. D. PY - 2015 DA - 2015// TI - Immune checkpoint blockade in Cancer therapy JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.59.4358 DO - 10.1200/JCO.2014.59.4358 ID - Postow2015 ER - TY - JOUR AU - Dougan, M. PY - 2017 DA - 2017// TI - Checkpoint blockade toxicity and immune homeostasis in the gastrointestinal tract JO - Front Immunol VL - 8 UR - https://doi.org/10.3389/fimmu.2017.01547 DO - 10.3389/fimmu.2017.01547 ID - Dougan2017 ER - TY - STD TI - Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–68. ID - ref7 ER - TY - JOUR AU - Haanen, J. AU - Carbonnel, F. AU - Robert, C. PY - 2017 DA - 2017// TI - Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx225 DO - 10.1093/annonc/mdx225 ID - Haanen2017 ER - TY - JOUR AU - Puzanov, I. AU - Diab, A. AU - Abdallah, K. PY - 2017 DA - 2017// TI - Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group JO - J Immunother Cancer VL - 5 UR - https://doi.org/10.1186/s40425-017-0300-z DO - 10.1186/s40425-017-0300-z ID - Puzanov2017 ER - TY - JOUR AU - Wang, Y. AU - Abu-Sbeih, H. AU - Mao, E. PY - 2018 DA - 2018// TI - Endoscopic and histologic features of immune checkpoint inhibitor-related colitis JO - Inflamm Bowel Dis VL - 24 UR - https://doi.org/10.1093/ibd/izy104 DO - 10.1093/ibd/izy104 ID - Wang2018 ER - TY - JOUR AU - Geukes Foppen, M. H. AU - Rozeman, E. A. AU - Wilpe, S. PY - 2018 DA - 2018// TI - Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management JO - ESMO Open VL - 3 UR - https://doi.org/10.1136/esmoopen-2017-000278 DO - 10.1136/esmoopen-2017-000278 ID - Geukes Foppen2018 ER - TY - STD TI - Hughes MS, Zheng H, Zubiri L, et al. Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control. Cancer Med. 2019. ID - ref12 ER - TY - JOUR AU - Abu-Sbeih, H. AU - Ali, F. S. AU - Alsaadi, D. PY - 2018 DA - 2018// TI - Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study JO - J Immunother Cancer. VL - 6 UR - https://doi.org/10.1186/s40425-018-0461-4 DO - 10.1186/s40425-018-0461-4 ID - Abu-Sbeih2018 ER - TY - JOUR AU - Abu-Sbeih, H. AU - Ali, F. S. AU - Wang, X. PY - 2019 DA - 2019// TI - Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis JO - J Immunother Cancer. VL - 7 UR - https://doi.org/10.1186/s40425-019-0577-1 DO - 10.1186/s40425-019-0577-1 ID - Abu-Sbeih2019 ER - TY - JOUR AU - Beck, K. E. AU - Blansfield, J. A. AU - Tran, K. Q. PY - 2006 DA - 2006// TI - Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 JO - J Clin Oncol VL - 24 UR - https://doi.org/10.1200/JCO.2005.04.5716 DO - 10.1200/JCO.2005.04.5716 ID - Beck2006 ER - TY - JOUR AU - Badran, Y. R. AU - Cohen, J. V. AU - Brastianos, P. K. AU - Parikh, A. R. AU - Hong, T. S. AU - Dougan, M. PY - 2019 DA - 2019// TI - Concurrent therapy with immune checkpoint inhibitors and TNFalpha blockade in patients with gastrointestinal immune-related adverse events JO - J Immunother Cancer VL - 7 UR - https://doi.org/10.1186/s40425-019-0711-0 DO - 10.1186/s40425-019-0711-0 ID - Badran2019 ER - TY - JOUR AU - Arbour, K. C. AU - Mezquita, L. AU - Long, N. PY - 2018 DA - 2018// TI - Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung Cancer JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2018.79.0006 DO - 10.1200/JCO.2018.79.0006 ID - Arbour2018 ER - TY - JOUR AU - Faje, A. l. e. x. a. n. d. e. r. T. AU - Lawrence, D. o. n. a. l. d. AU - Flaherty, K. e. i. t. h. AU - Freedman, C. h. r. i. s. t. i. n. e. AU - Fadden, R. i. l. e. y. AU - Rubin, K. r. i. s. t. a. AU - Cohen, J. u. s. t. i. n. e. AU - Sullivan, R. y. a. n. J. PY - 2018 DA - 2018// TI - High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma JO - Cancer VL - 124 UR - https://doi.org/10.1002/cncr.31629 DO - 10.1002/cncr.31629 ID - Faje2018 ER - TY - JOUR AU - Garcia-Neuer, M. AU - Marmarelis, M. E. AU - Jangi, S. R. PY - 2017 DA - 2017// TI - Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in Ipilimumab-treated advanced melanoma patients JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0302 DO - 10.1158/2326-6066.CIR-16-0302 ID - Garcia-Neuer2017 ER - TY - JOUR AU - Abu-Sbeih, H. AU - Ali, F. S. AU - Luo, W. AU - Qiao, W. AU - Raju, G. S. AU - Wang, Y. PY - 2018 DA - 2018// TI - Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis JO - J Immunother Cancer. VL - 6 UR - https://doi.org/10.1186/s40425-018-0411-1 DO - 10.1186/s40425-018-0411-1 ID - Abu-Sbeih2018 ER - TY - JOUR AU - Bello, E. AU - Cohen, J. V. AU - Mino-Kenudson, M. AU - Dougan, M. PY - 2019 DA - 2019// TI - Antitumor response to microscopic melanoma in the gastric mucosa mimicking ipilimumab-induced gastritis JO - J Immunother Cancer. VL - 7 UR - https://doi.org/10.1186/s40425-019-0524-1 DO - 10.1186/s40425-019-0524-1 ID - Bello2019 ER - TY - JOUR AU - Eshet, Y. AU - Baruch, E. N. AU - Shapira-Frommer, R. PY - 2018 DA - 2018// TI - Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study JO - Cancer Immunol Res. VL - 6 UR - https://doi.org/10.1158/2326-6066.CIR-17-0659 DO - 10.1158/2326-6066.CIR-17-0659 ID - Eshet2018 ER - TY - JOUR AU - Choi, K. AU - Abu-Sbeih, H. AU - Samdani, R. PY - 2019 DA - 2019// TI - Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? JO - Inflamm Bowel Dis VL - 25 UR - https://doi.org/10.1093/ibd/izy240 DO - 10.1093/ibd/izy240 ID - Choi2019 ER - TY - JOUR AU - Burke, K. E. AU - Ananthakrishnan, A. N. AU - Lochhead, P. PY - 2018 DA - 2018// TI - Identification of menopausal and reproductive risk factors for microscopic colitis-results from the Nurses' health study JO - Gastroenterology. VL - 155 UR - https://doi.org/10.1053/j.gastro.2018.08.029 DO - 10.1053/j.gastro.2018.08.029 ID - Burke2018 ER - TY - JOUR AU - Nguyen, G. C. AU - Smalley, W. E. AU - Vege, S. S. AU - Carrasco-Labra, A. AU - Committee, C. G. PY - 2016 DA - 2016// TI - American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis JO - Gastroenterology VL - 150 UR - https://doi.org/10.1053/j.gastro.2015.11.008 DO - 10.1053/j.gastro.2015.11.008 ID - Nguyen2016 ER - TY - JOUR AU - Weber, J. AU - Thompson, J. A. AU - Hamid, O. PY - 2009 DA - 2009// TI - A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1024 DO - 10.1158/1078-0432.CCR-09-1024 ID - Weber2009 ER - TY - JOUR AU - Schroeder, K. W. AU - Tremaine, W. J. AU - Ilstrup, D. M. PY - 1987 DA - 1987// TI - Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study JO - N Engl J Med VL - 317 UR - https://doi.org/10.1056/NEJM198712243172603 DO - 10.1056/NEJM198712243172603 ID - Schroeder1987 ER - TY - JOUR AU - Marthey, L. AU - Mateus, C. AU - Mussini, C. PY - 2016 DA - 2016// TI - Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease JO - J Crohns Colitis VL - 10 UR - https://doi.org/10.1093/ecco-jcc/jjv227 DO - 10.1093/ecco-jcc/jjv227 ID - Marthey2016 ER - TY - STD TI - Zhang ML, Neyaz A, Patil D, Chen J, Dougan M, Deshpande V. Immune-related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies. Histopathology. 2019. ID - ref29 ER - TY - JOUR AU - Malet, A. AU - Antoni, G. AU - Collins, M. PY - 2018 DA - 2018// TI - Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors JO - Eur J Cancer VL - 106 UR - https://doi.org/10.1016/j.ejca.2018.10.006 DO - 10.1016/j.ejca.2018.10.006 ID - Malet2018 ER -